‘COVID is Going to be a Cash Cow for Us’ … ‘That is Not What We Say to the Public’ … ‘People Won’t Like That’
- Jordon Trishton Walker, Pfizer Director of Research and Development, Strategic Operations – mRNA Scientific Planner: “One of the things we’re exploring is like, why don’t we just mutate it [COVID] ourselves so we could create — preemptively develop new vaccines, right? So, we have to do that. If we’re gonna do that though, there’s a risk of like, as you could imagine — no one wants to be having a pharma company mutating f**king viruses.”
- Walker: “Don’t tell anyone. Promise you won’t tell anyone. The way it [the experiment] would work is that we put the virus in monkeys, and we successively cause them to keep infecting each other, and we collect serial samples from them.”
- Walker: “You have to be very controlled to make sure that this virus [COVID] that you mutate doesn’t create something that just goes everywhere. Which, I suspect, is the way that the virus started in Wuhan, to be honest. It makes no sense that this virus popped out of nowhere. It’s bullsh*t.”
- Walker: “From what I’ve heard is they [Pfizer scientists] are optimizing it [COVID mutation process], but they’re going slow because everyone is very cautious — obviously they don’t want to accelerate it too much. I think they are also just trying to do it as an exploratory thing because you obviously don’t want to advertise that you are figuring out future mutations.”
Project Veritas released a new video today exposing a Pfizer executive, Jordon Trishton Walker, who claims that his company is exploring a way to “mutate” COVID via “Directed Evolution” to preempt the development of future vaccines.
Walker says that Directed Evolution is different than Gain-of-Function, which is defined as “a mutation that confers new or enhanced activity on a protein.” In other words, it means that a virus such as COVID can become more potent depending on the mutation / scientific experiment performed on it.
The Pfizer executive told a Veritas journalist about his company’s plan for COVID vaccines, while acknowledging that people would not like this information if it went public.
“One of the things we [Pfizer] are exploring is like, why don’t we just mutate it [COVID] ourselves so we could create — preemptively develop new vaccines, right? So, we have to do that. If we’re gonna do that though, there’s a risk of like, as you could imagine — no one wants to be having a pharma company mutating f**king viruses,” Walker said.
“From what I’ve heard is they [Pfizer scientists] are optimizing it [COVID mutation process], but they’re going slow because everyone is very cautious — obviously they don’t want to accelerate it too much. I think they are also just trying to do it as an exploratory thing because you obviously don’t want to advertise that you are figuring out future mutations,” he said.
“Don’t tell anyone. Promise you won’t tell anyone. The way it [the experiment] would work is that we put the virus in monkeys, and we successively cause them to keep infecting each other, and we collect serial samples from them.”
Walker drew parallels between this current Pfizer project and what may have happened at the Wuhan Institute of Virology in China.
“You have to be very controlled to make sure that this virus [COVID] that you mutate doesn’t create something that just goes everywhere. Which, I suspect, is the way that the virus started in Wuhan, to be honest. It makes no sense that this virus popped out of nowhere. It’s bullsh*t,” he said.
“You’re not supposed to do Gain-of-Function research with viruses. Regularly not. We can do these selected structure mutations to make them more potent. There is research ongoing about that. I don’t know how that is going to work.
Walker also told the Veritas journalist that COVID has been instrumental for Pfizer’s recent business success:
Walker: Part of what they [Pfizer scientists] want to do is, to some extent, to try to figure out, you know, how there are all these new strains and variants that just pop up. So, it’s like trying to catch them before they pop up and we can develop a vaccine prophylactically, like, for new variants. So, that’s why they like, do it controlled in a lab, where they say this is a new epitope, and so if it comes out later on in the public, we already have a vaccine working.
Veritas Journalist:Oh my God. That’s perfect. Isn’t that the best business model though? Just control nature before nature even happens itself? Right?
Walker:Yeah. If it works.
Veritas Journalist:What do you mean if it works?
Walker:Because some of the times there are mutations that pop up that we are not prepared for. Like with Delta and Omicron. And things like that. Who knows? Either way, it’s going to be a cash cow. COVID is going to be a cash cow for us for a while going forward. Like obviously.
Veritas Journalist:Well, I think the whole research of the viruses and mutating it, like, would be the ultimate cash cow.
Walker:Yeah, it’d be perfect.
Walker went on to explain how Big Pharma and government officials, such as at the Food & Drug Administration [FDA], have mutual interests, and how that is not in the best interest of the American people:
Walker:[Big Pharma] is a revolving door for all government officials.
Walker:In any industry though. So, in the pharma industry, all the people who review our drugs — eventually most of them will come work for pharma companies. And in the military, defense government officials eventually work for defense companies afterwards.
Veritas Journalist:How do you feel about that revolving door?
Walker:It’s pretty good for the industry to be honest. It’s bad for everybody else in America.
Veritas Journalist:Why is it bad for everybody else?
Walker:Because when the regulators reviewing our drugs know that once they stop regulating, they are going to work for the company, they are not going to be as hard towards the company that’s going to give them a job.
Tucker Carlson Reveals Email that Raises Questions About Hunter Biden’s Access to Classified Docs
Tucker Carlson and New York Post columnist Miranda Devine are raising new questions in the wake of now five different tranches of classified documents being found in Joe Biden’s home and at the Penn-Biden Center.
Part of the problem is what’s in those documents — if those documents pertain to Ukraine and things that involved Joe Biden’s family, that could be a big problem if he was taking documents to cover up things related to his family. We do know that some of the documents found at the Penn Biden Center were documents related to Ukraine, dated between 2013 and 2016 at the time Hunter Biden was most active in Burisma and Joe Biden was the point man on Ukraine.
Tucker Carlson highlighted a new email that had been found by Miranda Devine on the infamous laptop which they both believed was an indication of the use of classified information.
Devine wrote about the email which was from Hunter Biden to his then-business partner Devon Archer on April 13, 2014. It listed 22 points about Ukraine’s political situation.
As Carlson notes, it reads like it’s written by someone from the State Department with what the U.S. position would be laid out, for example, predicting an escalation of Russia’s “destabilization campaign, which could lead to a full-scale takeover of the eastern region, most critically Donetsk.”
“The strategic value is to create a land bridge for RU to Crimea. That won’t directly affect Burisma holdings but it will limit future UK exploration and utilization of offshore opportunities in particular,” Hunter wrote [….]
“It will also result in further destabilization of UK nationally and for whatever govt is in power. And the US will respond with even stronger sanctions. Those sanctions will threaten the tenuous support of the EU which does not have the political will to incur steep energy price increases.”
Point 22 makes my eyes go up as Hunter asked his partner to buy a “burner phone” — presumably to keep their conversations from being traced. “Buy a cell phone from a 7/11 or CVS tmrw and ill do the same.”
Hunter also notes in the email that this contract has to be done now — where they agree on the money “a retainer of 25k/p/m w/additional fees” — “not after the upcoming visit of my guy.” Joe Biden would visit Ukraine a week later.
That sure screams to me that there’s a big problem here, and they’re factoring in Joe Biden.
As Tucker noted, the government has had this email for years, but what have they done about it? Nothing that we can see. Carlson said they contacted the White House and asked if Hunter Biden had ever received classified information or a classified briefing. They did not respond to him.
Devine also noted something else that hasn’t been getting the notice that it deserves — the fact that DOJ not only retrieved the classified documents, but they also took for “further review” personally handwritten notes from the vice presidential years. Why would they take away notes? Well, there’s one big glaring reason — it would show that Joe Biden was commenting on the classified documents he took away and what he said about them — a further indication that this wasn’t a “surprise” that he had them and it might also reveal why he took them, as well as if the reason went beyond mere negligence into the cover-up realm.
MAJORITY of Americans vaccinated with bivalent Covid shot are NOT protected against falling ill
CDC report into new XBB.1.5 variant suggests — despite US paying $5bn for updated vaccines
Most Americans who get their bivalent booster vaccine are not protected against falling sick with Covid, official data suggests.
A report by the Centers for Disease Control and Prevention (CDC) released today found the updated shots were just 48 percent effective at stopping symptomatic infection caused by the XBB.1.5 subvariant for up to three months.
The CDC highlighted that the main purpose of the vaccines is to prevent hospitalization and death rather than transmission, and they are still expected to give high protection against severe illness.
But the findings mean the bivalent shots – which the US Government paid $5billion for last autumn – fall short of the World Health Organization’s 50 percent efficacy threshold for an effective vaccine.
When the original Pfizer and Moderna vaccines were developed in 2020, clinical trials indicated they could reduce rates of symptomatic infection by 95 percent.
The shot slowly loss effectiveness as the virus continued to mutate, though.
At one point, the average effectiveness against the virus had fallen as low as 36 percent.
The Omicron variant, which first emerged in late 2021, mutated an ability to evade protection provided by the shots.
Versions of the virus that have emerged since have continued to evolve with traits that allow it to bypass vaccine effectiveness.
This spurred vaccine manufacturers to develop new shots tailored to the Omicron variant.
These shots include the genetic code of Omicron along with that of the original strain that emerged in late 2019.
These bivalent shots were billed as being able to improve immunity against Omicron and its subvariants.
The US government paid $5 billion for the shots, which became available at the end of August.
In the time since, the XBB.1.5 subvariant has emerged as the most prevalent strain in American – making up 49 percent of CDC sequenced cases.
Bivalent shots are now the only available Covid shot, with the originally formulated vaccines now having been replaced.
The CDC researchers gathered data from a government Covid testing initiative from December 1 of last year to January 22 for the study.
Using the information on whether tested subjects were vaccinated and overall population vaccine data, they determined a 48 percent overall effectiveness of the bivalent shot against the XBB.1.5 subvariant.
In almost all age groups, the shot had an effectiveness of around 40 to 50 percent from two weeks to three months after getting the additional booster.
This was also the fourth or fifth vaccine dose for many study participants, with most Americans already had gotten the original two-dose regimen and a booster shot.
The effectiveness is slightly lower than the 52 percent efficacy the shot has against the BA.5 variant, which emerged in the US over the summer.
Among those aged 65 and older, effectiveness fell to 37 percent against BA.5 and 43 percent against XBB/XBB.1.5.
Despite their limited effectiveness against infection, the CDC reports that hospitalizations and deaths were still limited – and declared the vaccine rollout a success.
The rampant spread of the Omicron variant in recent months also means that much of the population has natural immunity to the virus – and little to worry about from it.
While the results may surprise some, experts have previously dubbed XBB.1.5 as the most vaccine-resistant strain of the virus to emerge yet.
There was initial panic among some scientists due to the variant’s highly mutated spike protein, leading to some experts to call it the most vaccine-resistant strain ever.
But a study by the Centers for Disease Prevention & Control (CDC) has shown that the updated booster helped prevent illness in roughly half of people who had previously received two to four doses of the Covid shot.
The researchers looked at Covid cases from December 2022 to January 13, 2023, when the XBB/XBB.1.5 variant was dominant.
The estimates are for symptomatic infection, which the CDC defined as one or more symptom of Covid.
Dr Brendan Jackson, head of the US CDC Covid response, said that the updated vaccine reduced the risk of death from Covid by more than twofold, compared with vaccinated people who had not received the bivalent booster.
And compared to people who are unvaccinated, the updated shot reduced the risk of death from Covid nearly 13-fold.
Study author Ruth Link-Gelles of the CDC said overall, the vaccines cut the risk of symptomatic infection by about half on a population, but individuals see a different benefit depending on their risk factors.
Only 15 percent of the US population have received the updated Covid booster shot so far, according to CDC data.
The bivalent jabs were touted as being able to boost protection against the Omicron strain, but several studies suggest they are no more effective than the original Covid shots.
Made by Moderna and Pfizer, the updated vaccines were advertised as being able to boost protection against Omicron subvariants that have become world-dominant.
The US Government spent $3.4 billion in taxpayer money for 105million doses of the shots to help protect against the mild but highly transmissible strains this winter. Britain has purchased at least 26million doses for an undisclosed fee.
Government data showed XBB.1.5 was estimated to make up nearly half of US cases in the week ending January 21.
The variant is so infectious because it binds better to cells than other XXB Omicron strains.